In this episode our hosts Katie McMurry, PharmD (US Transplant MSL) and Amber Lawson, PharmD (US Transplant MSL) have a conversation with Dr. Michael Verneris, MD. Dr. Verneris is a Professor of Pediatrics and the Barton Family Endowed Chair of Bone Marrow Transplant at the University of Colorado Denver School of Medicine. He also serves as the Director of Bone Marrow Transplantation and Cellular Therapy at the Children’s Hospital Colorado. In addition, he is currently serving as Vice Chair of the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Dr. Verneris will take us through some of the impacts socioeconomic status has on hematopoietic cell transplant outcomes in the pediatric population as well as some of the data gaps that need to be addressed going forward in this patient population.

Supporting Literature and References:

1. “Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis”https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845011/
2. “Prevalence and Impact of Financial Hardship among New England Pediatric Stem Cell Transplantation Families” https://pubmed.ncbi.nlm.nih.gov/25445021/
3. “Social determinants of health predict health outcomes following pediatric allogeneic hematopoietic stem cell transplant” https://pubmed.ncbi.nlm.nih.gov/38302730/
4. “Social regulation of human gene expression: mechanisms and implications for public health” https://pubmed.ncbi.nlm.nih.gov/23927506/
5. “The conserved transcriptional response to adversity” https://pubmed.ncbi.nlm.nih.gov/31592179/
6. “Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment” https://pubmed.ncbi.nlm.nih.gov/27219347/
7. “Low socioeconomic status, adverse gene expression profiles, and clinical outcomes in hematopoietic stem cell transplant recipients” https://pubmed.ncbi.nlm.nih.gov/26286914/
8. “Molecular correlates of socioeconomic status and clinical outcomes following hematopoietic cell transplantation for leukemia” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859844/
9. “The health risk of social disadvantage is transplantable into a new host” https://pubmed.ncbi.nlm.nih.gov/39008669/
10. “Mindfulness-Based Stress Reduction training reduces loneliness and pro-inflammatory gene expression in older adults: A small randomized controlled trial” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635809/
11. “Yogic meditation reverses NF-kappa B and IRF-related transcri

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

In this episode our hosts Jessica Driscoll, DNP (US Transplant MSL) and Katie McMurry, PharmD (US Transplant MSL) have a conversation with Amanda Ferraro, a patient advocate for chronic graft-versus-host disease and the complications associated with stem cell transplant. A leukemia and stem cell transplant survivor, Amanda lives with chronic graft-versus-host disease and speaks candidly about her journey. Her mission is to help others by validating the challenges associated with stem cell transplant and facilitating these crucial conversations.

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

In this episode our hosts Jason Yeh, PharmD (US Transplant MSL) and Katie McMurry, PharmD (US Transplant MSL) have a conversation with Dr. Sagar Patel, an Assistant Professor in the Transplant and Cellular Therapy Program at the Huntsman Cancer Institute in Salt Lake City, Utah. In this episode, Dr. Patel discusses current transplantation barriers observed in the diagnosis and treatment of chronic graft versus host disease, the existing tools utilized to improve outcomes and potential innovations to mitigate barriers.

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

In this episode our MSL co-hosts Yiota Manolopoulos, PharmD, MPH and Katie Mousavi, PharmD have a conversation with Anne Peters, MD on how to incorporate social determinants of health in clinical trials and methods to overcome the challenges that under resourced communities face daily. Dr. Peters identifies key barriers that physicians and other healthcare providers encounter when designing clinical trials for patients with diabetes, particularly among racial and ethnic minority populations and other marginalized communities. We conclude the episode with concrete actions and resources our listeners can use to design clinical trials, ensure longevity of these interventions, and begin to narrow the gap on healthcare disparities within the racial and ethnic minority populations with diabetes.

This program is non-promotional and sponsored by Sanofi. The presenter was compensated by Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

Supporting literature from episode:

1. Social Determinants of Health at CDC: https://www.cdc.gov/about/sdoh/index.html
2. Social Determinants of Health and Diabetes: A Scientific Review: https://doi.org/10.2337/dci20-0053
3. The multidisciplinary team in diagnosing and treatment of patients with diabetes and comorbidities: A scoping review: https://doi.org/10.1177/26335565231165966

Music: Spark of Inspiration by Shane Ivers - https://www.silvermansound.com

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

Despite having a lower reported prevalence of atrial fibrillation, contemporary data suggest underrepresented racial and ethnic populations experience disparities in atrial fibrillation treatment and health outcomes. Join our MSL co-hosts Dalila Masic, PharmD and Teresa Russell, PharmD as they have a conversation with Larry R. Jackson, II, MD, MHSc. What does the literature show about atrial fibrillation detection, management, and outcomes in underrepresented populations with atrial fibrillation? How can clinicians partner with patients to help bridge these gaps? Dr. Jackson shares his insights from years of clinical experience and research on health equity and racial/ethnic differences in arrhythmia care.

This program is non-promotional and sponsored by Sanofi. The presenter was compensated by Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

Resources mentioned in episode:

1. American College of Cardiology CardioSmart Tools: https://www.cardiosmart.org/topics/atrial-fibrillation

2. Healthwise Shared Decision Making Tools: https://www.healthwise.org/solutions/care-transformation.aspx

Supporting literature from episode:

1. Racial and Ethnic Considerations in Patients with Atrial Fibrillation: JACC Focus Seminar 5/9: https://pubmed.ncbi.nlm.nih.gov/34887142/

2. Racial/Ethnic Differences in Atrial Fibrillation Symptoms, Treatment Patterns, and Outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry: https://pubmed.ncbi.nlm.nih.gov/26995367/

3. Differences by Race/Ethnicity in the Prevalence of Clinically Detected and Monitor-Detected Atrial Fibrillation: MESA: https://pubmed.ncbi.nlm.nih.gov/31934795/

4. Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities: https://pubmed.ncbi.nlm.nih.gov/34238436/

5. Under-Reporting and Under-Representation of Racial/Ethnic Minorities in Major Atrial Fibrillation Clinical Trials: https://doi.org/10.1016/j.jacep.2020.03.001

6. Racial and Ethnic Disparities in Arrhythmia Care: A Call for Action: https://pubmed.ncbi.nlm.nih.gov/35842408/

Music: Spark of Inspiration by Shane Ivers - https://www.silvermansound.com

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

The leading cause of death among women globally is cardiovascular disease. Despite this, cardiovascular disease in women remains understudied, underdiagnosed, and undertreated. Join our MSL co-hosts Dalila Masic, PharmD and Kinsi Brindley, PharmD as they have a conversation with Dr. Annabelle Volgman, MD, FACC, FAHA. What can we do to help close the gender gap for women with atrial fibrillation? Dr. Volgman shares her insights that she has established through years of experience and research in treating women with cardiovascular disease.

Resources mentioned in episode:

1. WomenHeart: https://www.womenheart.org/

Supporting literature from episode:

1. Women and Atrial Fibrillation Review Article: https://ncbi.nlm.nih.gov/pmc/articles/PMC8281363/
2. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study: https://pubmed.ncbi.nlm.nih.gov/16198847/
3. Gendered social determinists of health and risk of major adverse outcomes in atrial fibrillation: https://www.jacc.org/doi/10.1016/S0735-1097%2823%2902103-4
4. Sex Differences in Early Rhythm Control of Atrial Fibrillation in the EAST-AFNET 4 Trial: https://www.sciencedirect.com/science/article/pii/S073510972207663X?via%3Dihub
5. Association of Women Authors With Women Enrollment in Clinical Trials of Atrial Fibrillation: https://www.ahajournals.org/doi/full/10.1161/JAHA.121.024233

Music: Spark of Inspiration by Shane Ivers - https://www.silvermansound.com

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

In this episode our hosts Sara Hammad, PharmD (US Transplant Associate Medical Director) and Ryan Bookout, PharmD (US Transplant MSL) have a conversation with Dr. Joseph Scalea, MD. Dr. Scalea is the inaugural Vice Chair of Innovation in the Department of Surgery, the Surgical Director of Kidney Transplant, and the Director of Hepatology, Nephrology, and Transplant ICCE Quality and Innovation at the Medical University of South Carolina. Dr. Scalea will take us through the past, present, and future of how innovation has and can help bridge the disparities gap seen in kidney transplantation today.

Music: Spark of Inspiration by Shane Ivers - https://www.silvermansound.com

MAT-US-2306343 (v1.0). Approved for Distribution. Exp: 08-02-2025.

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

Join our Sanofi Medical co-hosts, Dalila Masic, Amulya Tatachar and Sara Hammad as we sit down with Subarna Malakar, Head of Diversity, Equity & Inclusion (DE&I) North America and Global Specialty Care at Sanofi. In this episode, Subarna speaks to personal experiences that relate to his passion for health equity. We also discuss Sanofi’s approach to DE&I, and Subarna’s role in leading these initiatives.

Link to A Million Conversations: https://www.sanofi.com/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations

Music: Spark of Inspiration by Shane Ivers - https://www.silvermansound.com

This program is non-promotional and sponsored by Sanofi. Presenter(s) were compensated and/or received an honorarium from Sanofi in connection with this program. This program does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources and information may be available and should be investigated.

This podcast is intended for US residents only. Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.